Bacillus strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. Bacillus strains, compositions and methods are disclosed for providing beneficial effects to animals, including but not limited to increasing performance of the animal.

This invention relates to novel probiotic Bifidobacteria strains, particularly, B. pseudocatenulatum strains, and their use as probiotic, and food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of obesity, diabetes, and related conditions.

A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.

A method of producing coated microcapsules comprises the steps of producing microcapsules by cold gelation having a denatured or hydrolysed protein matrix and an active agent contained within the matrix, and drying the microcapsules. A meltable coating composition comprising wax and oil and configured to have a melting point of about 70° C. to about 100° C. is heated to a temperature above the melting point of the meltable coating composition to melt the meltable coating composition, and the microcapsules are coated with the melted meltable coating composition

The disclosure relates generally to bacterial strains of the genus Butyricimonas, e.g., Butyricimonas faecihominis bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such strains. The disclosure further relates to methods of using such strains and compositions for preventing or treating a disorder, e.g., a cancer, when administered to a subject in need thereof.

The present invention provides a Lactobacillus composition and a use thereof for improving anxiety caused by antibiotics, wherein the Lactobacillus composition comprises Lactobacillus plantarum GMNL-141, Lactobacillus rhamnosus GM-020, Lactobacillus acidophilus GMNL-185, or a combination thereof. The Lactobacillus composition can effectively improve imbalance of an individual's intestinal flora caused by antibiotics to help stabilize and increase species richness and increase the synthesis of mood-stabilizing compounds, including flavonoids, flavonols, isoquinoline alkaloids, niacinamide, nicotinamide, and short-chain fatty acids in intestine, and thus effectively improve antibiotic-induced with anxiety disorders.

The present disclosure provides a probiotics of PTA22 from rabbits, a nutritional composition for preparing food of rabbits and a composition for rabbits to degrade oxalic acid. Through this disclosure, the health of rabbits can be ensured and the resistance to pathogenic bacteria can be improved after rabbits consume the food containing PTA22. As well, the probiotic PTA22 can help rabbits reduce the risk of hypercalciuria and calculus.

The present invention relates to a composition comprising Rhodospirillum rubrum cells for use in a method for inhibiting the uptake of cholesterol from the intestine in a human subject, such that the plasma LDL-cholesterol level in said human subject is lowered and concentrations of blood proteins relating to kidney function, liver function and/or heart function are essentially unaltered. In addition, the invention relates to a non-therapeutic method of lowering plasma LDL-cholesterol level in a subject, the method comprising administering to the subject a composition comprising Rhodospirillum rubrum cells, wherein lowering of the plasma LDL-cholesterol level is the inhibition of the uptake of cholesterol from the intestine in said human subject. Furthermore, the invention relates to a food product, a feed product, a food stuff and a food supplement comprising Rhodospirillum rubrum cells and having plasma LDL-cholesterol level lowering properties relating to intestinal cholesterol uptake inhibitory properties.

The present application relates to a Bifidobacterium breve or progeny thereof. Specifically, the present application relates to Bifidobacterium breve 207-1 and a composition, culture, food product or dietary supplement containing the same. The present application also relates to the use of Bifidobacterium breve 207-1 and the composition, culture, food product or dietary supplement containing the same in medicine.

The invention relates to bacteria of the Christensenellaceae family and to compositions including same for use in the prevention and/or treatment of pathological muscle loss and/or of at least one disease characterized by muscle loss in humans or animals.